Logotype for H. Lundbeck

H. Lundbeck (LUN) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for H. Lundbeck

Q3 2026 earnings summary

11 Nov, 2026

Executive summary

  • 9M 2026 revenue reached DKK 20,191m, up 13% CER (9% in DKK); underlying growth was 11% CER after excluding a DKK 470m Partner Markets inventory build.

  • Vyepti and Rexulti led growth; strategic brands rose 16% CER to DKK 15,951m.

  • Adjusted EBITDA increased 19% CER to DKK 7,026m; net debt/EBITDA fell to 0.7x from 1.3x a year earlier.

  • FY 2026 revenue growth guidance rose to 11%-12% CER and adjusted EBITDA growth to 15%-19% CER.

  • Commercial momentum, pipeline progress and a reshaped operating model support the 2027 Scale phase.

Financial highlights

  • 9M EBIT rose 13% in DKK to DKK 5,409m; net profit increased 30% to DKK 4,073m.

  • Adjusted net profit was DKK 5,369m and adjusted EPS was DKK 5.42, up 25%; reported EPS was DKK 4.11, up 30%.

  • Q3 revenue was DKK 6,603m, up 7% CER; adjusted EBITDA was DKK 2,261m, up 17% CER.

  • 9M operating cash flow was DKK 5,010m; free cash flow was DKK 4,557m versus DKK 4,151m.

Outlook and guidance

  • FY 2026 growth guidance increased to 11%-12% for revenue and 15%-19% for adjusted EBITDA, both at CER, from prior ranges of 7%-9% and 8%-14%.

  • Adjusted gross margin guidance is 86%-87%; R&D costs DKK 5.6bn-DKK 5.7bn; D&A ~DKK 1.9bn; net debt DKK 4.0bn-DKK 5.0bn.

  • Q4 growth is expected to moderate as the DKK 470m Partner Markets inventory build does not recur; Trintellix generic entry and increased Rexulti competition also weigh on the outlook.

  • Bexicaserin DEEP OCEAN results were expected in Q4 2026, DEEP SEA in Q1 2027; amlenetug pivotal results are expected in Q3 2027.

  • Mid-term targets remain mid-single-digit revenue CAGR for 2023-2027 and adjusted EBITDA margin above 30% in 2027, excluding business development activity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from H. Lundbeck